Axsome Therapeutics, Inc (AXSM) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Pharmaceutical Preparations
Price History
5-Year Weekly Candlestick Chart
Profile
growth, profitability, earnings quality and valuation lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-0.7%)0/25
- P/S (15.2x)5/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-345.0%)0/25
- Net margin (-26.6%)0/25
- Operating margin (-24.4%)0/25
- Financial Health62/100 · Moderate
- Altman Z (7.15)25/25
- Current ratio (1.39)12/25
- Interest coverage (-27.0x)0/25
- Net cash / debt (Net cash)25/25
- Quality21/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (-1.66)6/25
- FCF conversion (n/a)0/25
- Margin stability (σ 88.9%)0/25
About Axsome Therapeutics, Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Show more
It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Headquarters: NEW YORK, NY · Employees: 925 · Website ↗
Analyst Consensus
Strong BuyWall Street consensus estimates — not a PMP forecast · Updated Sep 21, 2026
Insider Transactions
Recent SEC Form 4 filings
- SellOption exercise · filed 2026-08-07-4660 sh2026-08-06
- SellOpen market sale · filed 2026-08-07-4660 sh2026-08-06
- BuyOption exercise · filed 2026-08-07+4.7K sh2026-08-06
- SellOption exercise · filed 2026-08-07-45004 sh2026-08-05
- SellOpen market sale · filed 2026-08-07-45004 sh2026-08-05
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-0.7%D
Grade D: NegativeTTM FCF / Market Cap — vs own 5Y history: -8.8%–-0.5% · 92nd pct
P/S (TTM)15.19xD
Grade D: Exp.Price / TTM Revenue (own statements) — vs own 5Y history: 9.9x–95.8x · 32nd pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales13.6xD
Grade D: V.Exp.Enterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E85.7xD
Grade D: Exp.Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio197.12xD
Grade D: V.Exp.Price to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.94B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-345.0%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-27.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-26.6%D
Grade D: LowNet Income / Revenue
Operating Margin-24.4%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin-24.4%D
Grade D: LowGross Profit / Revenue
FCF Margin-10.0%D
Grade D: LowFCF / Revenue
True FCF Margin-23.3%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
62BAltman Z-Score7.15A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.39xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.99xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-27.0xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.1xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity2.16xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt2.59xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Forward Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue13.3%D
Grade D: HighTTM stock-based comp / TTM Revenue
Quality
9/9 Loss Years21EPiotroski F-Score5/9C
Grade C: AvgFinancial strength 0–9. >7 Strong
Beneish M-Score-1.66D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability88.9%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.0%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.68xC
Grade C: AvgRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$6.43
Cash & short-term investments per share (Finnhub)
Book Value / Share$1.16
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$117.85M
Total debt obligations (short + long term)
Cash & Equiv.$305.11M
Cash and short-term investments
Net Debt$-187.26MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$54.59M
Shareholders' equity (book value)
Asset / Liability1.08xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$10.76B
Current Market Capitalization
Beta0.81B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
AXSM spája excelentnú finančnú stabilitu a nulové zadlženie s nulovou ziskovosťou a záporným cash flow, čo pri súčasnom vysokom ocenení obmedzuje jej okamžitú investičnú atraktivitu.
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 22, 2026
Key Insights: Axsome Therapeutics, Inc (AXSM)
Composite verdict for Axsome Therapeutics, Inc: AXSM spája excelentnú finančnú stabilitu a nulové zadlženie s nulovou ziskovosťou a záporným cash flow, čo pri súčasnom vysokom ocenení obmedzuje jej okamžitú investičnú atraktivitu.. Piotroski F-Score of 5/9 indicates mixed fundamentals for Axsome Therapeutics, Inc. Altman Z-Score of 7.15 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -1.66 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny. Free-cash-flow margin is negative (-10%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -27.0× leaves little room for earnings shocks.
- Axsome Therapeutics, Inc posted a net loss in 9 of 9 available completed fiscal years (2016–2025).
- At a valuation score of 25/100, AXSM trades at a premium to its historical multiples.
See how AXSM ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for AXSM in the last 30 days.
See AXSM move history →Frequently Asked Questions about AXSM
Is AXSM stock a buy right now?
PreMarketPrice's quantitative model rates Axsome Therapeutics, Inc's financial health at 62/100 — AXSM spája excelentnú finančnú stabilitu a nulové zadlženie s nulovou ziskovosťou a záporným cash flow, čo pri súčasnom vysokom ocenení obmedzuje jej okamžitú investičnú atraktivitu.. This is a data-driven snapshot of fundamentals, not investment advice.
Is AXSM stock overvalued?
Axsome Therapeutics, Inc trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Axsome Therapeutics, Inc report earnings?
No confirmed earnings date is currently scheduled for AXSM. The Earnings section lists recent reports and updates as dates are announced.
What sector does Axsome Therapeutics, Inc operate in?
Axsome Therapeutics, Inc operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Axsome Therapeutics, Inc do?
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company.
About Axsome Therapeutics, Inc (AXSM) Stock
Axsome Therapeutics, Inc (AXSM) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. Real-time pricing data for Axsome Therapeutics, Inc is available on this page with a market capitalization of $10.8 billion. The financial health score for AXSM is 62/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for AXSM stock.
AXSM Stock Analysis & Key Metrics
On PreMarketPrice, you can track Axsome Therapeutics, Inc (AXSM) across multiple dimensions:
- Pre-market price & movement: Real-time AXSM stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for AXSM with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Axsome Therapeutics, Inc across multiple reporting periods.
- Financial health score: A composite score of 62/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for AXSM.
- Sector peers: Compare AXSM against 10 other healthcare stocks on key financial metrics.
Is AXSM a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Axsome Therapeutics, Inc (AXSM) as an investment. The financial health score of 62/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Axsome Therapeutics, Inc (AXSM) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.